Britain covid-19 information vaccine Britain

Oxford Biomedica enters Covid-19 vaccine manufacturing deal

Reading now: 670
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.UK-based gene and cell therapy group Oxford Biomedica has entered a supply agreement with AstraZeneca UK for large-scale production of Covid-19 vaccine candidate, AZD1222.

The 18-month supply deal is part of a three-year master supply and development agreement between the companies, which may choose to expand the supply period for an additional 18 months into 2022 and 2023.

According to the agreement, AstraZeneca will make an upfront payment of £15m to Oxford Biomedica as a capacity reservation fee.

Based on manufacturing scale-up and continuation of the vaccine programme, Oxford Biomedica may get additional payments in excess.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA